Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Carcinoma|Breast Lump|Edema|Erythema|Estrogen Receptor Negative|HER2/Neu Negative|Inflammatory Breast Carcinoma|Invasive Breast Carcinoma|Peau d'Orange|Progesterone Receptor Negative|Triple-Negative Breast Carcinoma
Interventions: DRUG: Carboplatin|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|BIOLOGICAL: Panitumumab
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)